Yahoo Finance • 4 days ago
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded NetEase (NTES) to Ov... Full story
Yahoo Finance • 5 days ago
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food... Full story
Yahoo Finance • 5 days ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 11 days ago
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an... Full story
Yahoo Finance • 18 days ago
(RTTNews) - Cidara Therapeutics, Inc. (CDTX), a biotechnology company, on Friday announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of its drug candidate CD388 in populations at h... Full story
Yahoo Finance • 18 days ago
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN... Full story
Yahoo Finance • 20 days ago
[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] Cidara Therapeutics (NASDAQ:CDTX [https://seekingalpha.com/symbol/CDTX]) added ~15% on Wednesday after the biotech announced an accelerated timeline for a Phase 3... Full story
Yahoo Finance • 20 days ago
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA a... Full story
Yahoo Finance • 21 days ago
In recent trading, shares of Cidara Therapeutics Inc (Symbol: CDTX) have crossed above the average analyst 12-month target price of $74.00, changing hands for $75.47/share. When a stock reaches the target an analyst has set, the analyst l... Full story
Yahoo Finance • last month
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company mana... Full story
Yahoo Finance • 2 months ago
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertiv Holdings Co (Symbol: VRT), where a total of 65,043 contracts have traded so far, representing approximately 6.5 million und... Full story
Yahoo Finance • 2 months ago
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $70.00 from $69.00 on Friday, while maintaining a Buy rating following the company’s second-quarter 2025 earnings release. The $1.37 billion m... Full story
Yahoo Finance • 2 months ago
Investing.com - Citizens JMP has raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $66.00 from $59.00, while maintaining a Market Outperform rating. The company, currently valued at $1.37 billion, has seen its stock surge ove... Full story
Yahoo Finance • 2 months ago
Investing.com - RBC Capital raised its price target on Cidara Therapeutics (NASDAQ:CDTX) stock to $115.00 from $75.00 on Wednesday, while maintaining an Outperform rating. The biotech company, now valued at $1.35 billion, has delivered rem... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compen... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to... Full story
Yahoo Finance • 3 months ago
LONDON - Contract research organization hVIVO PLC (AIM:HVO) announced Monday that its client Cidara Therapeutics (NASDAQ:CDTX) has achieved positive topline results in a Phase 2b field study for CD388, a drug designed to prevent seasonal i... Full story
Yahoo Finance • 4 months ago
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clos... Full story
Yahoo Finance • 4 months ago
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the clo... Full story
Yahoo Finance • 4 months ago
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pric... Full story